Entrada Therapeutics, Inc. (TRDA)
NASDAQ: TRDA · Real-Time Price · USD
5.85
-0.20 (-3.31%)
Jul 24, 2026, 4:00 PM EDT - Market closed
Entrada Therapeutics Market Cap
Entrada Therapeutics has a market cap or net worth of $210.8 million as of July 24, 2026. Its market cap has decreased by -6.43% in one year.
Market Cap
210.80M
Enterprise Value
5.69M
1-Year Change
-6.43%
Ranking
Category
Stock Price
$5.85
ChartMarket Cap Chart
Since the IPO on October 29, 2021, Entrada Therapeutics's market cap has decreased from $251.01M to $210.80M, a decrease of -16.02%. That is a compound annual growth rate of -3.62%.
| Date | Market Cap | % Change |
|---|---|---|
| Jul 24, 2026 | 210.80M | -42.82% |
| Dec 31, 2025 | 368.66M | -39.78% |
| Dec 31, 2024 | 612.16M | 21.70% |
| Dec 29, 2023 | 503.01M | 18.72% |
| Dec 30, 2022 | 423.70M | -20.71% |
| Dec 31, 2021 | 534.36M | 112.88% |
| Oct 29, 2021 | 251.01M | - |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Anavex Life Sciences | 229.83M |
| Galectin Therapeutics | 227.21M |
| Protara Therapeutics | 227.07M |
| Nautilus Biotechnology | 224.93M |
| Adagene | 222.66M |
| AC Immune | 222.21M |
| Compugen | 221.33M |
| Coherus Oncology | 220.58M |